molmed

Investors

5th tranche of the share capital increase reserved to Société Générale (“SEF") completed

5th tranche of the share capital increase reserved to Société Générale (“SEF") completed ▾

Investors

Utilization request concerning the 5th tranche of the share capital increase to be reserved to Société Générale ("SEF") submitted

Utilization request concerning the 5th tranche of the share capital increase to be reserved to Société Générale ("SEF") submitted ▾

Investors

Full results of NGR-hTNF trial in mesothelioma published by the leading research journal The Lancet Oncology. New clinical outcome of NGR-hTNF in brain lymphomas will be presented at ASCO.

Full results of NGR-hTNF trial in mesothelioma published by the leading research journal The Lancet Oncology. New clinical outcome of NGR-hTNF in brain lymphomas will be presented at ASCO. ▾

News & Events

Stay update

Immunotherapy in Hematological Malignancies 2018 ▾

Immunotherapy in Hematological Malignancies 2018

Location: Cuneo

News & Events

Stay update

American Society of Gene and Cell Therapy (ASGCT) ▾

American Society of Gene and Cell Therapy (ASGCT)

Location: Chicago

News & Events

Stay update

Riunione Nazionale GITMO XII Congresso della Società GITMO ▾

Riunione Nazionale GITMO XII Congresso della Società GITMO

Location: Bologna

Investors

2018 First Quarter Results

2018 First Quarter Results ▾

Investors

MolMed signs Master Service Agreement with Boston Children’s Hospital for the supply of lentiviral vectors

MolMed signs Master Service Agreement with Boston Children’s Hospital for the supply of lentiviral vectors ▾

Investors

Publication of the minutes of Shareholders Meeting of April 12nd 2018

Publication of the minutes of Shareholders Meeting of April 12nd 2018 ▾

Investors

MolMed Corporate Presentation ARM Investor Day NYC April 17 2018

MolMed Corporate Presentation ARM Investor Day NYC April 17 2018 ▾

Last presentation

DOWNLOAD

Subscribe to

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.